RegeneRx (OTCQB: RGRX) is focused on the development of therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair and regeneration, according to the company’s website (see here: www.regenerx.com). SNNLive caught up with J.J. Finkelstein, President and CEO of RegeneRx Biopharmaceuticals, Inc. at the LD Micro "Main Event" 2016 in Bel Air, CA.
In this video interview, Mr. Finkelstein and our host discuss the following topics:
- Overview of RegeneRx Biopharmaceuticals, Inc.
- Update since our last interview (click here)
- Clinical Development
For more information about RegeneRx Biopharmaceuticals, Inc., please visit: www.regenerx.com
The interview may contain forward-looking statements about RegeneRx Biopharmaceuticals, Inc. See RegeneRx Biopharmaeuticals' periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions